Blog
RSS FeedPosted by Michael Wonder on 10 Mar 2020
Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes
9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps. ...
Posted by Michael Wonder on 04 Mar 2020
Novartis receives Health Canada approval for Mayzent (siponimod) to treat secondary progressive multiple sclerosis with active disease
3 March 2020 - Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of people living ...
Posted by Michael Wonder on 03 Mar 2020
Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura
2 March 2020 - Cablivi is the first treatment approved in Canada for aTTP, a life-threatening blood clotting disorder. ...
Posted by Michael Wonder on 28 Feb 2020
Nuvo Pharmaceuticals announces Health Canada approves Suvexx for the acute treatment of migraine
27 February 2020 - Canadian launch anticipated in the second half of 2020. ...
Posted by Michael Wonder on 26 Feb 2020
Janssen receives Health Canada approval of Balversa (erdafitinib), the first FGFR kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations
24 February 2020 - Diagnostic testing is available to identify which patients are most likely to benefit from BALVERSA, offering a ...
Posted by Michael Wonder on 12 Feb 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis)
11 February 2020 - Eli Lilly Canada announced today that Health Canada approved Taltz (ixekizumab) on 4 February 2020, for the ...
Posted by Michael Wonder on 29 Jan 2020
Health Canada approves new indication for Invokana (canagliflozin) to reduce the risks associated with diabetic kidney disease in patients with type 2 diabetes
28 January 2020 - INVOKANA® is the only diabetes treatment in Canada approved to treat this patient group ...
Posted by Michael Wonder on 28 Jan 2020
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime
27 January 2020 - Jubilant Radiopharma announced today that the company received approval from Health Canada for Drax Exametazine (Kit ...
Posted by Michael Wonder on 28 Jan 2020
Health Canada approves new indication for Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis
27 January 2020 - In the Phase 3 pivotal trial, nearly 44% of patients receiving Stelara subcutaneous injections every 8 ...
Posted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 16 Jan 2020
Cimzia (certolizumab pegol) now approved in Canada for the treatment of non-radiographic axial spondyloarthritis
15 January 2020 - UCB Canada announced today that Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults ...
Posted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...
Posted by Michael Wonder on 09 Jan 2020
New treatment approved in Canada for most common type of leukaemia
8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 08 Jan 2020
AbbVie receives Health Canada approval of Rinvoq (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis
7 January 2020 - Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis program, one ...